HomeQuestion

In a patient with inflammatory triple-positive breast cancer who has a pCR to neoadjuvant chemotherapy, but has an incidentally found focus of intermediate-grade ER+/PR+/HER2- ILC in the mastectomy specimen, how would this impact your adjuvant radiation recommendations?

1 Answers

Mednet Member

Radiation Oncology · Varian Medical Systems/Allegheny health network

I would treat it like a principle for inflammatory breast cancer, where I consider a scar boost even for pCR or boost any undissected GTV nodes.

In a patient with inflammatory triple-positive breast cancer who has a pCR to neoadjuvant chemotherapy, but has an incidentally found focus of intermediate-grade ER+/PR+/HER2- ILC in the mastectomy specimen, how would this impact your adjuvant radiation recommendations? | Mednet